Hairy Cell Leukemia
34
9
15
9
Key Insights
Highlights
Success Rate
69% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.8%
4 terminated out of 34 trials
69.2%
-17.3% vs benchmark
0%
0 trials in Phase 3/4
100%
9 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 9 completed trials
Clinical Trials (34)
Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
Rituximab+ Zanubrutinib for Patients With Hairy Cell Leukemia and Hairy Cell Variant
Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)
Assessment of Disease Burden in Hairy Cell Leukemia